Taken together these evidence may explain the suboptimal activity and the lower clinical benefits obtained in MKIs-treated RET-positive NSCLC, compared to the outcomes of other oncogene-addicted NSCLC subtypes when treated with matched targeted therapies. Here, RET is linked to non-small cell lung carcinoma.